{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+Abilify",
    "query": {
      "intervention": "Drug Abilify"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 90,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Drug+Abilify&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T05:02:14.253Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00149734",
      "title": "Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Ondansetron followed by placebo",
          "type": "DRUG"
        },
        {
          "name": "Placebo followed by Ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 8,
      "start_date": "2005-01",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2021-08-13",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00149734"
    },
    {
      "nct_id": "NCT02574741",
      "title": "Combination Treatment for Augmenting Language in Children With ASD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Behavioral Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "5 Years to 11 Years"
      },
      "enrollment_count": 58,
      "start_date": "2012-06",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2020-04-29",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02574741"
    },
    {
      "nct_id": "NCT01942187",
      "title": "A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder",
        "Dysthymic Disorder",
        "Depressive Disorder Not Otherwise Specified (NOS)"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Bupropion",
          "type": "DRUG"
        },
        {
          "name": "Problem Solving Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-08",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2019-04-18",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01942187"
    },
    {
      "nct_id": "NCT03881449",
      "title": "DIMES - DIgital MEdicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia",
        "Major Depressive Disorder",
        "Bi-Polar Disorder",
        "Schizo Affective Disorder"
      ],
      "interventions": [
        {
          "name": "ABILIFY MYCITE",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Durham VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2019-04-04",
      "completion_date": "2021-11",
      "has_results": false,
      "last_update_posted_date": "2020-06-18",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03881449"
    },
    {
      "nct_id": "NCT01432444",
      "title": "Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Aripiprazole (Abilify®) IM Depot Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 493,
      "start_date": "2011-09",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-05-07",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 119,
      "location_summary": "Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01432444"
    },
    {
      "nct_id": "NCT06482554",
      "title": "Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Apathy",
        "Schizophrenia",
        "Schizophrenia; Psychosis"
      ],
      "interventions": [
        {
          "name": "Lumateperone 42 mg",
          "type": "DRUG"
        },
        {
          "name": "Risperidone 2 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Louisiana State University Health Sciences Center Shreveport",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2024-06",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 1,
      "location_summary": "Shreveport, Louisiana",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06482554"
    },
    {
      "nct_id": "NCT07483294",
      "title": "Cerebellum-based Imaging Neural Markers for Antipsychotic Response",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Psychosis; Acute"
      ],
      "interventions": [
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 120,
      "start_date": "2025-11-01",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07483294"
    },
    {
      "nct_id": "NCT05554627",
      "title": "VA Aripiprazole vs Esketamine for Treatment Resistant Depression",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "Esketamine",
          "type": "DRUG"
        },
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-10-27",
      "completion_date": "2023-10-27",
      "has_results": false,
      "last_update_posted_date": "2024-01-05",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 26,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05554627"
    },
    {
      "nct_id": "NCT00712270",
      "title": "Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kettering Health Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 21,
      "start_date": "2005-04",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 1,
      "location_summary": "Kettering, Ohio",
      "locations": [
        {
          "city": "Kettering",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00712270"
    },
    {
      "nct_id": "NCT02918370",
      "title": "Aripiprazole for Bipolar Disorder and Alcohol Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar Disorder",
        "Alcoholism",
        "Alcohol Abuse"
      ],
      "interventions": [
        {
          "name": "Aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 75,
      "start_date": "2016-11",
      "completion_date": "2023-06-30",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-15T05:02:14.253Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02918370"
    }
  ]
}